Compare Duke Energy Corp (DUK) vs Cassava Sciences Inc (FLNA) Price & Performance

Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.

DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.